Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/21892105/ below:

Cost-effectiveness of computed tomography screening for lung cancer in the United States

Affiliations

• ¹ Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA. pamela@mgh-ita.org

• PMID: 21892105
• PMCID: PMC3202298
• DOI: 10.1097/JTO.0b013e31822e59b3

Item in Clipboard

Pamela M McMahon et al. J Thorac Oncol. 2011 Nov.

• ¹ Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA. pamela@mgh-ita.org

• PMID: 21892105
• PMCID: PMC3202298
• DOI: 10.1097/JTO.0b013e31822e59b3

Item in Clipboard

Introduction: A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.

Methods: Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.

Results: Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.

Conclusions: The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.

PubMed Disclaimer

• A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions.

  Villanti AC, Jiang Y, Abrams DB, Pyenson BS. Villanti AC, et al. PLoS One. 2013 Aug 7;8(8):e71379. doi: 10.1371/journal.pone.0071379. Print 2013. PLoS One. 2013. PMID: 23940744 Free PMC article.

• Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.

  Goffin JR, Flanagan WM, Miller AB, Fitzgerald NR, Memon S, Wolfson MC, Evans WK. Goffin JR, et al. Lung Cancer. 2016 Nov;101:98-103. doi: 10.1016/j.lungcan.2016.09.013. Epub 2016 Sep 28. Lung Cancer. 2016. PMID: 27794416

• Cost-effectiveness of Lung Cancer Screening in Canada.

  Goffin JR, Flanagan WM, Miller AB, Fitzgerald NR, Memon S, Wolfson MC, Evans WK. Goffin JR, et al. JAMA Oncol. 2015 Sep;1(6):807-13. doi: 10.1001/jamaoncol.2015.2472. JAMA Oncol. 2015. PMID: 26226181

• Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review.

  Raymakers AJN, Mayo J, Lam S, FitzGerald JM, Whitehurst DGT, Lynd LD. Raymakers AJN, et al. Appl Health Econ Health Policy. 2016 Aug;14(4):409-418. doi: 10.1007/s40258-016-0226-5. Appl Health Econ Health Policy. 2016. PMID: 26873091 Review.

• 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.

  Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, Moore D. Wang D, et al. Health Technol Assess. 2008 Feb;12(2):iii-iv, ix-xi, 1-135. doi: 10.3310/hta12020. Health Technol Assess. 2008. PMID: 18093448 Review.

• Challenges of quitting smoking and lung cancer screening.

  Carreras G, Gorini G. Carreras G, et al. Ann Transl Med. 2017 Dec;5(24):488. doi: 10.21037/atm.2017.09.40. Ann Transl Med. 2017. PMID: 29299450 Free PMC article. No abstract available.

• Exploring Novel Technologies in Lung Cancer Diagnosis: Do We Have Room for Improvement?

  Sharma M, Surani S. Sharma M, et al. Cureus. 2020 Jan 31;12(1):e6828. doi: 10.7759/cureus.6828. Cureus. 2020. PMID: 32181072 Free PMC article. Review.

• A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings.

  Toumazis I, Alagoz O, Leung A, Plevritis SK. Toumazis I, et al. Cancer. 2021 Dec 1;127(23):4432-4446. doi: 10.1002/cncr.33835. Epub 2021 Aug 12. Cancer. 2021. PMID: 34383299 Free PMC article.

• Understanding the perceived benefits, barriers, and cues to action for lung cancer screening among Latinos: A qualitative study.

  Alaniz-Cantú EI, Goodwin K, Smith L, Acosta E, Chávez-Iñiguez A, Evans MJ, Gaitán M, Lei F, Yousefi-Nooraie R, Fiscella KA, Rivera MP, Cupertino AP, Cartujano-Barrera F. Alaniz-Cantú EI, et al. Front Oncol. 2024 Mar 20;14:1365739. doi: 10.3389/fonc.2024.1365739. eCollection 2024. Front Oncol. 2024. PMID: 38571494 Free PMC article.

• Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.

  Ten Haaf K, Tammemägi MC, Bondy SJ, van der Aalst CM, Gu S, McGregor SE, Nicholas G, de Koning HJ, Paszat LF. Ten Haaf K, et al. PLoS Med. 2017 Feb 7;14(2):e1002225. doi: 10.1371/journal.pmed.1002225. eCollection 2017 Feb. PLoS Med. 2017. PMID: 28170394 Free PMC article.

1. 1. [Accessed November 4, 2010];National Lung Screening Trial Results. 2010 at http://www.cancer.gov/newscenter/pressreleases/NLSTresultsRelease.
2. 1. The National Lung Screening Trial: Overview and Study Design. Radiology. 2010 - PMC - PubMed
3. 1. Dominioni L, Rotolo N, Poli A, et al. Self-Selection Effects in Smokers Attending Lung Cancer Screening: A 9.5-Year Population-Based Cohort Study in Varese, Italy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 - PubMed
4. 1. Cox LS, Clark MM, Jett JR, et al. Change in smoking status after spiral chest computed tomography scan screening. Cancer. 2003;98:2495–501. - PubMed
5. 1. Townsend CO, Clark MM, Jett JR, et al. Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening. Cancer. 2005;103:2154–62. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3